- Online training -
Webcode 24112457
Dr. Steffen Groß
Paul-Ehrlich-Institut (PEI), Langen
Steffen Gross has extensive experience in molecular and cell biology. Mr. Gross joined the Paul-Ehrlich Institute in 2005 and became Head of the Section monoclonal and polyclonal antibodies in 2012. Due to re-structure of the section he became Head of Section Quality and Non-clinical Evaluation of Antibody therapeutics" in 2022. He is involved in the assessment of the quality and preclinical issues for marketing authorization applications, scientific advices and clinical trial applications. Until 2012 Mr. Gross was laboratory head of the section monoclonal and polyclonal antibodies and involved in testing of immunoglobulins, immunsera and monoclonal antibodies. Before joining the Paul-Ehrlich Institute he worked in the Netherland for three years as a postdoc. During this time he had been working several months at the National Institute of Health in Bethesda. After his return to Germany in 2001 he became a research group leader at the University of Frankfurt.
André Mota
ASPHALION S.L., Madrid Office, Spain
Regulatory Affairs Director,
Madrid Office
André has more than 14 years' experience in CMC Regulatory Affairs and Product Lifecycle Management of Human Medicinal Products in different countries, with several types of products, and for different types of companies.
Besides his core CMC expertise, he is mainly focused on CMC writing and strategic guidance, he has also been deeply involved in other relevant areas, such as:
- Project lead/management of global projects,
- Implementation of EMA Policy 0070 (clinical data transparency), and
- eCTD publishing.
More information please click here.
Dr. Helmut Vigenschow
ViPharmaService, Burgrieden
Independent Consultant
28/11/2024
28/11/2024
9:00 am - 5:00 pm online seminar
You may dial in 30 minutes before the training starts
online
online
Event - 1,190 € plus tax
The participation fee includes documentation for download, a certificate, access to the Learning Space and technical support including PreMeeting.
Event - 1,190 € plus tax
The participation fee includes documentation for download, a certificate, access to the Learning Space and technical support including PreMeeting.
Dr. Birgit Wessels
Conference Manager
+49 6221 500-652
b.wessels@forum-institut.de
To make the most of ICH Q12 opportunities, you have to be aware of the relation between ICH guidelines Q8 to Q12 and how to properly integrate them. Our experts will go through each guideline and train you on the desired outcome of mastering the processes from development to lifecycle management and especially QbD.
You are involved in product lifecycle management processes? Stop asking if Quality by Design is mandatory or needed! Our three experts will sensitise you not to underestimate any longer what you can in fact get from it.
To make the most of ICH Q12 opportunities you have to be aware of the relation between ICH guidelines Q8 to Q12 and how to properly integrate them. It's absolutely critical that you understand the need of mastering the different Quality by Design (QbD) options and that you realise their implications.
Our experts will go through each guideline with focus on ICH Q8 (drug product) and ICH Q11 (drug substance). They will point out the specific challenges with interpretation and implementation and the relation between all guidelines.
In the end you will be trained in a more conceptional way on the desired outcome of mastering QbD to make the most of ICH Q12.
After participating in this seminar you will be aware of the relation between the guidelines ICH Q8 to ICH Q12. This will enable you to recognise the opportunities of ICH Q12 and to profitably put the requirements of the guideline into practice.
09:00 Opening and introduction round
09:15
Dr Steffen Groß
09:45
Dr Steffen Groß
10:20 Coffee break
10:30
André Mota
12:30 Lunch break
13:30
Dr Helmut Vigenschow
15:00
Dr Helmut Vigenschow
16:15 Coffee break
16:30
Dr Steffen Groß and André Mota
17:00 End of the training
Seit 2000 bieten wir Expertenwissen zu verschiedenen Rechtsthemen in englischer und deutscher Sprache an. Zu unseren Kernkompetenzen gehören u.a. das Stoff- und Chemikalienrecht sowie das Pharmarecht.
This course can be choosen as elective module within the modular qualification training course "CMC-Specialist in Regulatory Affairs".
The concept:
- First you visit the mandatory module "Der CMC-Manager in Regulatory Affairs"
- Further you choose another three elective modules (= three training days) dealing with CMC related topics from our portfolio
- Thus you receive a structured training in CMC/Regulatory Affairs topics
- Thus you are able to qualify yourself individually according to your focus of activities
Please visit our webpage Website
FORUM Institut’s all-in-one training platform uses the latest teaching methods.
All our online training courses take place in the Learning Space, our holistic learning environment with many features that promote effective and sustainable learning.
of 5 stars of all ratings from 2023
of 5 stars on Trustpilot = good
Enhance your skills in writing key pharmacovigilance safety documents. In this two-day online seminar, gain not just a b...
The compact course with a content focus on the development, production and analytics of biotech drugs. Secure your place...
LAST CALL! - CANCELLATION DEADLINE: 29.04.2024 - Variation regulation, classification guideline, eSubmission, variation ...
Regulatory expectations regarding risk management for pharmaceuticals in (emerging) markets often contend with the strin...
Learn how to prepare your pharmacovigilance system in Germany, Europe and worldwide for an upcoming inspection in this o...
We are now officially certified to ISO 9001 and ISO 21001 standard.
Details
